Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
Por:
Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J
Publicada:
1 jun 2015
Resumen:
Purpose: The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer signaling. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of MEHD7945A.
Experimental Design: Patients with locally advanced or metastatic epithelial tumors received escalating doses of MEHD7945A (1-30 mg/kg) every 2 weeks (q2w) until disease progression or intolerable toxicity. An expansion cohort was enrolled at the recommended phase II dose (14 mg/kg, q2w). Plasma samples, tumor biopsies, FDG-PET were obtained for assessment of pharmacokinetics, and pharmacodynamic modulation downstream of EGFR and HER3.
Results: No dose-limiting toxicities or MEHD7945A-related grade >= 4 adverse events (AE) were reported in dose-escalation (n = 30) or expansion (n = 36) cohorts. Related grade 3 AEs were limited to diarrhea and nausea in the same patient (30 mg/kg). Related AEs in >= 20% of patients <= 24 hours after the first infusion included grade 1/2 headache, fever, and chills, which were managed with premedication and/or symptomatic treatment. Pharmacodynamic data indicated target inhibition in 25% of evaluable patients. Best response by RECIST included 2 confirmed partial responses in squamous cell carcinomas of head and neck (SCCHN) patients with high tumor tissue levels of the HER3 ligand heregulin; 14 patients had stable disease >= 8 weeks, including SCCHN (n = 3), colorectal cancer (n = 6), and non-small cell lung cancer (n = 3).
Conclusions: MEHD7945A was well-tolerated as single agent with evidence of tumor pharmacodynamic modulation and antitumor activity in SCCHN. Phase II studies were initiated with flat (nonweight-based) dosing at 1,100 mg q2w in SCCHN and colorectal cancer. (C) 2015 AACR.
Filiaciones:
Juric D:
Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Dienstmann R:
Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
Cervantes A:
Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain
Hidalgo M:
Spanish National Cancer Research Center, Madrid, Spain
Messersmith W:
University of Colorado Cancer Center, Denver, Colorado
Blumenschein GR:
University of Texas MD Anderson Cancer Center, Houston, Texas
Tabernero J:
Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
Roda D:
Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain
Calles A:
Spanish National Cancer Research Center, Madrid, Spain
Jimeno A:
University of Colorado Cancer Center, Denver, Colorado
Wang X:
Genentech, Inc., South San Francisco, California
Bohórquez SS:
Genentech, Inc., South San Francisco, California
Leddy C:
Genentech, Inc., South San Francisco, California
Littman C:
Genentech, Inc., South San Francisco, California
Kapp AV:
Genentech, Inc., South San Francisco, California
Shames DS:
Genentech, Inc., South San Francisco, California
Penuel E:
Genentech, Inc., South San Francisco, California
Amler LC:
Genentech, Inc., South San Francisco, California
Pirzkall A:
Genentech, Inc., South San Francisco, California
Baselga J:
Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
|